Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 8, 2017

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Bipolar Disorder
Interventions
DRUG

lurasidone

Atypical Antipsychotic

OTHER

Placebo

Inactive substance

Trial Locations (9)

44106

University Hospitals Cleveland Medical Center, Cleveland

02115

The Brigham and Women's Hospital, Department of Psychiatry, Boston

V6T 1Z3

UBC Mood Disorders Center, Vancouver

807-8555

Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu

570-8506

Department of Neuropsychiatry, Kansai Medical University, Moriguchi-shi

060-8638

Department of Psychiatry, Hokkaido University Graduate School of Medicine, Kita-ku

187-8551

National Center of Neurology and Psychiatry, Kodaira

470-1192

Department of Psychiatry, Fujita Health University School of Medicine, Aichi

SE5 8AF

Institute of Psychiatry, Psychology and Neuroscience,King's College London, London

All Listed Sponsors
lead

Lakshmi N Yatham

OTHER

NCT02731612 - Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients | Biotech Hunter | Biotech Hunter